SBIR/STTR Research Award

A tunable laser scanning system for rapid analysis of biopharmaceutical formulations

Award identifier cf37b482bf6d2aef9bbd8e1c7ad848900662fe1509bdc52b7505e488e0eb5c62Awarding agency Department of Health and Human Services · National Institutes of Health

Award amount

$2,146,232

Program and phase

SBIR · Phase II

Award year

2024

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
National Institutes of Health
Recipient company
NIRRIN TECHNOLOGIES INC
Proposal award date
2024-09-03
Contract end date
2026-07-31
UEI
EBCFNPZNYMC1
Solicitation number
PA20-272
Topic code
400

Research abstract

Project Summary The goal of this Direct to Phase II SBIR proposal is continue development of Nirrin’s proprietary tunable laser spectrometry system in preparation for commercialization. Biomanufacturing at commercial scale requires precise monitoring of product components, including active pharmaceutical ingredients (APIs) such as proteins, peptides, and nucleic acids, but also supporting excipients which are essential for overall safety and efficacy. Process errors can lead to incorrect concentrations of APIs and excipients leading to extremely costly process revisions and millions of dollars of waste in the form of adulterated product. Nirrin Technologies, Inc. has developed the NXT platform, a rapid and sensitive instrument for the simultaneous analysis of biopharmaceutical APIs and excipients from a single sample with zero up-front sample preparation. The system relies on tunable laser spectrometry, scanning samples across multiple wavelengths and compiling absorbance spectra unique to the given analyte. Absorbance spectra have been developed and validated for dozens of biopharmaceutical API’s and excipients and can be rapidly analyzed via Nirrin’s straightforward software user interface. The NXT workflow has been evaluated by multiple biopharmaceutical companies and satisfies many of the key product requirements which competing technologies do not. An foreseen challenge with the current Phase II project is the need for validated standards to be used for customer validation as well as post-installation quality assessment. Aim 1 has been largely completed, optimizing system design, however, Aim 2 will significantly benefit from the supplement proposed here. Often reagents generated by customers have significant errors from batch to batch, and so highly controlled standards must be generated. The company has previously relied on NIST-validated reagents; however many customers are using custom reagents that are not available in NIST-qualified aliquots. Supplemental funding is therefore requested to acquire quantification instrumentation for both protein (Repligen SoloVPE System) and small molecules (Agilent HPLC). These will be used to test standards, as well as produce sets of qualified dilution series for multiple reagents for aim 3 external validation at customer sites.

Technology keywords

Not reported

Awards with the same topic code

Verified by an exact topic code match. This is not a text-similarity match.

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.